188 related articles for article (PubMed ID: 28608993)
1. Oral fluoropyrimidine versus intravenous 5-fluorouracil for the treatment of advanced gastric and colorectal cancer: Meta-analysis.
Zhang L; Xing X; Meng F; Wang Y; Zhong D
J Gastroenterol Hepatol; 2018 Jan; 33(1):209-225. PubMed ID: 28608993
[TBL] [Abstract][Full Text] [Related]
2. Oral versus intravenous fluoropyrimidines for colorectal cancer.
Chionh F; Lau D; Yeung Y; Price T; Tebbutt N
Cochrane Database Syst Rev; 2017 Jul; 7(7):CD008398. PubMed ID: 28752564
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of oxaliplatin plus capecitabine or infusional fluorouracil/leucovorin in patients with metastatic colorectal cancer: a pooled analysis of randomized trials.
Arkenau HT; Arnold D; Cassidy J; Diaz-Rubio E; Douillard JY; Hochster H; Martoni A; Grothey A; Hinke A; Schmiegel W; Schmoll HJ; Porschen R
J Clin Oncol; 2008 Dec; 26(36):5910-7. PubMed ID: 19018087
[TBL] [Abstract][Full Text] [Related]
4. Oral uracil-tegafur plus leucovorin vs fluorouracil bolus plus leucovorin for advanced colorectal cancer: a meta-analysis of five randomized controlled trials.
Bin Q; Li J; Liao C; Cao Y; Gao F
Colorectal Dis; 2011 Aug; 13(8):837-45. PubMed ID: 20050863
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer.
; Piedbois P; Rougier P; Buyse M; Pignon J; Ryan L; Hansen R; Zee B; Weinerman B; Pater J; Leichman C; Macdonald J; Benedetti J; Lokich J; Fryer J; Brufman G; Isacson R; Laplanche A; Levy E
J Clin Oncol; 1998 Jan; 16(1):301-8. PubMed ID: 9440757
[TBL] [Abstract][Full Text] [Related]
6. Capecitabine Versus Continuous Infusion Fluorouracil for the Treatment of Advanced or Metastatic Colorectal Cancer: a Meta-analysis.
Wu Z; Deng Y
Curr Treat Options Oncol; 2018 Nov; 19(12):77. PubMed ID: 30483908
[TBL] [Abstract][Full Text] [Related]
7. First-line protracted venous infusion fluorouracil with CisDDP or carboplatin in advanced colorectal cancer.
Garcia-Giralt E; Beuzeboc P; Deffontaines D; Diéras V; Dorval T; Jouve M; Palangie T; Scholl S; Pouillart P
J Infus Chemother; 1996; 6(3):149-51. PubMed ID: 9229328
[TBL] [Abstract][Full Text] [Related]
8. Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study.
Van Cutsem E; Twelves C; Cassidy J; Allman D; Bajetta E; Boyer M; Bugat R; Findlay M; Frings S; Jahn M; McKendrick J; Osterwalder B; Perez-Manga G; Rosso R; Rougier P; Schmiegel WH; Seitz JF; Thompson P; Vieitez JM; Weitzel C; Harper P;
J Clin Oncol; 2001 Nov; 19(21):4097-106. PubMed ID: 11689577
[TBL] [Abstract][Full Text] [Related]
9. A meta-analysis of chemotherapy regimen fluorouracil/leucovorin/oxaliplatin compared with fluorouracil/leucovorin in treating advanced colorectal cancer.
Chen ML; Fang CH; Liang LS; Dai LH; Wang XK
Surg Oncol; 2010 Mar; 19(1):38-45. PubMed ID: 19345093
[TBL] [Abstract][Full Text] [Related]
10. High-dose infusional 5-fluorouracil combination therapy of metastatic gastric and colorectal cancer.
Loeffler TM; Hausamen TU
J Infus Chemother; 1996; 6(3):137-40. PubMed ID: 9229325
[TBL] [Abstract][Full Text] [Related]
11. Randomized phase II study of second-line chemotherapy with the best available 5-fluorouracil regimen versus weekly administration of paclitaxel in far advanced gastric cancer with severe peritoneal metastases refractory to 5-fluorouracil-containing regimens (JCOG0407).
Nishina T; Boku N; Gotoh M; Shimada Y; Hamamoto Y; Yasui H; Yamaguchi K; Kawai H; Nakayama N; Amagai K; Mizusawa J; Nakamura K; Shirao K; Ohtsu A;
Gastric Cancer; 2016 Jul; 19(3):902-10. PubMed ID: 26386560
[TBL] [Abstract][Full Text] [Related]
12. Fluorouracil modulation in colorectal cancer: lack of improvement with N -phosphonoacetyl- l -aspartic acid or oral leucovorin or interferon, but enhanced therapeutic index with weekly 24-hour infusion schedule--an Eastern Cooperative Oncology Group/Cancer and Leukemia Group B Study.
O'Dwyer PJ; Manola J; Valone FH; Ryan LM; Hines JD; Wadler S; Haller DG; Arbuck SG; Weiner LM; Mayer RJ; Benson AB
J Clin Oncol; 2001 May; 19(9):2413-21. PubMed ID: 11331320
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of capecitabine versus 5-fluorouracil in colorectal and gastric cancers: a meta-analysis of individual data from 6171 patients.
Cassidy J; Saltz L; Twelves C; Van Cutsem E; Hoff P; Kang Y; Saini JP; Gilberg F; Cunningham D
Ann Oncol; 2011 Dec; 22(12):2604-2609. PubMed ID: 21415237
[TBL] [Abstract][Full Text] [Related]
14. Prospectively randomized North Central Cancer Treatment Group trial of intensive-course fluorouracil combined with the l-isomer of intravenous leucovorin, oral leucovorin, or intravenous leucovorin for the treatment of advanced colorectal cancer.
Goldberg RM; Hatfield AK; Kahn M; Sargent DJ; Knost JA; O'Connell MJ; Krook JE; Maillard JA; Wiesenfeld M; Schaefer PL; Tirona MT; Moertel CG
J Clin Oncol; 1997 Nov; 15(11):3320-9. PubMed ID: 9363861
[TBL] [Abstract][Full Text] [Related]
15. Randomized multicenter phase II trial of bolus plus infusional fluorouracil/leucovorin compared with fluorouracil/leucovorin plus oxaliplatin as third-line treatment of patients with advanced colorectal cancer.
Kemeny N; Garay CA; Gurtler J; Hochster H; Kennedy P; Benson A; Brandt DS; Polikoff J; Wertheim M; Shumaker G; Hallman D; Burger B; Gupta S
J Clin Oncol; 2004 Dec; 22(23):4753-61. PubMed ID: 15570076
[TBL] [Abstract][Full Text] [Related]
16. Toxicity of fluorouracil in patients with advanced colorectal cancer: effect of administration schedule and prognostic factors.
; Lévy E; Piedbois P; Buyse M; Pignon JP; Rougier P; Ryan L; Hansen R; Zee B; Weinerman B; Pater J; Leichman C; Macdonald J; Benedetti J; Lokich J; Fryer J; Brufman G; Isacson R; Laplanche A; Quinaux E; Thirion P
J Clin Oncol; 1998 Nov; 16(11):3537-41. PubMed ID: 9817272
[TBL] [Abstract][Full Text] [Related]
17. Multicenter phase III study of uracil/tegafur and oral leucovorin versus fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer.
Douillard JY; Hoff PM; Skillings JR; Eisenberg P; Davidson N; Harper P; Vincent MD; Lembersky BC; Thompson S; Maniero A; Benner SE
J Clin Oncol; 2002 Sep; 20(17):3605-16. PubMed ID: 12202661
[TBL] [Abstract][Full Text] [Related]
18. 5-fluorouracil administered as a 48-hour chronomodulated infusion in combination with leucovorin and cisplatin: a randomized phase II study in metastatic colorectal cancer.
Falcone A; Allegrini G; Masi G; Lencioni M; Pfanner E; Brunetti I; Danesi R; Bocci G; Del Tacca M; Conte P
Oncology; 2001; 61(1):28-35. PubMed ID: 11474245
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety assessment of S-1-based regimens comparing to intravenous fluorouracil-based ones in Asian patients with metastatic colorectal carcinoma: A system review and meta-analysis.
Chen J; Wang J
Medicine (Baltimore); 2019 Jun; 98(23):e15999. PubMed ID: 31169742
[TBL] [Abstract][Full Text] [Related]
20. Randomized, open-label, phase III study of a 28-day oral regimen of eniluracil plus fluorouracil versus intravenous fluorouracil plus leucovorin as first-line therapy in patients with metastatic/advanced colorectal cancer.
Schilsky RL; Levin J; West WH; Wong A; Colwell B; Thirlwell MP; Ansari RH; Bell WN; White RL; Yates BB; McGuirt PV; Pazdur R
J Clin Oncol; 2002 Mar; 20(6):1519-26. PubMed ID: 11896100
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
